Provider review
Hers Review: GLP-1 Evidence and Follow-Up
Hers offers branded GLP-1 treatment with a separately billed membership. Product-specific evidence, contraception and pregnancy discussions, and a clear follow-up plan are more useful than a headline weight-loss promise.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit HersOf Hers’s 1 dated product claim documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. Evidence for a medicine does not establish the quality of this provider’s care.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
FDA-approved
Phase 3 trials
Not confirmed
September 2025
Provenance
Products reviewed at Hers
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Zepbound
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 1 product reviewed here. The evidence concerns the molecule, not Hers's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Hers’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
ZepboundTirzepatide · FDA-approvedClaim matches the trials
“Wegovy®, Zepbound®, and Foundayo™ are FDA approved for weight loss.”
Read on the Hers site, October 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Trial of the manufacturer product, not a trial of this provider’s service or every compounded preparation.
The approved finished product has clinical evidence for its labeled population. Approval is not a guarantee of a particular patient’s result or a validation of the platform itself.2
Dispensing chain
Who actually fills your prescription
Read the full account
The reviewed public offer does not identify the pharmacy assigned to an individual prescription. Obtain the dispensing pharmacy’s name and contact details from the care team; a platform name is not that identification.
Read on the Hers site, October 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
For an FDA-approved finished medicine, confirm the manufacturer product, pharmacy, packaging and prescription label. A public patient-specific certificate is not the standard used here to judge an approved drug. This review did not independently inspect a dispensed package or trace an individual prescription through its supply chain.
Read on the Hers site, October 2026.
Licensing
Licensed to dispense, and where
Coverage
The public offer says treatment is not available in every state; confirm the exact product and location.
Read the full licensing claim
Clinical eligibility and state availability require confirmation. This review does not infer nationwide service from an online offer or independently verify every clinician license.
Read on the Hers site, October 2026.
Regulatory
The FDA warning letter
Issued September 2025
Hims & Hers Health, Inc. dba Hers — 716825. Concerns marketing and labeling.
Read the full allegation
FDA found compounded semaglutide advertising implied equivalence with approved drugs and was false or misleading.
What has changed since
October 2026 public catalog prominently lists branded medicines. Current close-out status is not asserted.
Assessment
What holds up, and what does not
- Public menu distinguishes named prescription products.
- Membership terms distinguish care fees from medicine.
- The platform describes ongoing care rather than an isolated sale.
- A women-focused brand does not establish an individualized reproductive-health plan.
- Starting medication prices exclude membership and may not describe every term.
- The exact clinician, pharmacy and state availability still require confirmation.
Verdict
The bottom line
Before committing, identify the exact medicine, the clinician responsible for follow-up, the dispensing pharmacy and the total charge. Match the evidence to that product and your treatment goal.
Opens Hers' website. A link is not a recommendation to take anything.
Hers offers several paths, and they need separate evidence
The October 2026 Hers weight-loss page lists branded GLP-1 products and a separate membership. That creates several decisions: whether treatment is appropriate, which product fits, whether a pill or injection is suitable, and whether the care service offers the follow-up you need. A women-focused brand does not answer those clinical questions by itself. 1
This review evaluates public information, not a personal treatment experience. We did not test clinical response times, obtain a prescription or verify an individual pharmacy assignment. Those limits matter when judging convenience and service quality.
Full analysis — 4 more sectionsZepbound’s evidence concerns a defined treatment · Reproductive-health questions belong in the care plan · The membership is additional to medication · How the historical FDA letter should be read
Zepbound’s evidence concerns a defined treatment
FDA’s weight-management approval for Zepbound was based on randomized, double-blind, placebo-controlled trials in adults with obesity or overweight and a weight-related condition. The treatment was studied with diet and activity measures. This provides a real clinical basis for the approved drug; it is not a promise that a particular member will reproduce an average result. 2
A provider should connect the proposed medicine to your diagnosis and health history. Ask what benefit is expected, how response will be evaluated and how side effects affect the plan. The value of follow-up is the ability to reassess that decision, rather than simply continue a subscription because the next shipment is scheduled.
The medication menu also includes oral and injectable semaglutide options. Different formulations have their own evidence and instructions. A result from an injection trial cannot be used as the estimated result of any pill bearing the same molecule name. Our evidence comparison separates the major drug programs without ranking every delivery format as interchangeable.
Reproductive-health questions belong in the care plan
For a patient considering tirzepatide, oral contraception is a specific issue to discuss. The Zepbound label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. That is a product-label instruction, not a prediction of what will happen to an individual’s contraception. 3
The label also addresses pregnancy and fetal risk. Discuss pregnancy intentions, a possible pregnancy and other medicines with the prescribing clinician rather than treating weight-loss treatment as separate from reproductive care. The tirzepatide and oral contraception guide explains why the timing matters. 3
These are useful tests of a care service: can the clinical team review the full medication list, explain a relevant interaction and coordinate a change with the clinician already managing contraception? General customer support and clinical advice are different services. Ask which route handles each before a time-sensitive question arises.
The membership is additional to medication
The public offer lists a $39 first membership month and $149 monthly renewals. Medicine is separate; examples include Zepbound vial and KwikPen offers from $299 per month. These are offer-level amounts, not a verified total for every prescribed strength, term or patient. Membership does not guarantee that a clinician will prescribe. 1
Budgeting should include what happens when the plan changes. Request the price of the prescribed presentation, the recurring membership amount and the terms for pausing or ending care. If a clinician decides another treatment is more suitable, ask which charges have already been earned and which future charges can stop. Do not assume that cancellation of a membership reverses a pharmacy order.
The Hers Wegovy pill page describes medication billing separately, monthly or upfront depending on the plan. The payment schedule therefore matters as much as the monthly equivalent. A larger upfront charge may create a different commitment even when the displayed monthly figure appears similar. 4
How the historical FDA letter should be read
FDA sent Hers a September 9, 2025 warning letter about compounded semaglutide marketing that implied equivalence with approved drugs. It is relevant to evaluating claim precision. It does not establish a defect in every branded product now listed, nor does this review assert a current close-out status. 5
The fair standard is formulation-specific. Approved medicines have product-specific labeling; compounded preparations are not FDA-approved. A marketing label such as personalized care does not replace that distinction. Ask whether the proposed treatment is an approved finished drug and obtain the pharmacy’s identity when the prescription is arranged. 6
Hers deserves consideration where its care model fits the patient’s needs. The strongest decision rests on a named medicine, an appropriate clinical plan and clear ongoing access. A familiar brand or a before-and-after story cannot establish those things on its own.
Questions
Frequently asked questions
Does every Hers GLP-1 have the same evidence?
No. The molecule, approved formulation, indication and treatment schedule matter. Evidence for an injection does not automatically establish the result of a different oral formulation.
Why discuss oral contraception before tirzepatide?
The Zepbound label has a specific four-week precaution after starting and after each dose increase. Review contraception and other medicines with the prescriber.
Is medication included in membership?
The current public offer bills membership and medicine separately. Confirm both amounts and any upfront term before paying.
Compare
Others selling what Hers sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Hers is on
Method
How we checked this
Non-product facts last checked October 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Hers's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- Hers (2026). Weight-loss program and membership terms. Hers; accessed October 13, 2026. the Hers site
- FDA (2023). FDA approves new medication for chronic weight management. FDA; accessed October 13, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- Eli Lilly / DailyMed (2026). Zepbound prescribing information. Eli Lilly / DailyMed; accessed October 13, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Hers (2026). Wegovy pill public product page. Hers; accessed October 13, 2026. the Hers site
- FDA (2025). Warning letter to Hims & Hers Health, Inc. dba Hers,716825. FDA; accessed October 13, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-716825-09092025
- FDA (2026). Understanding the risks of compounded drugs. FDA; accessed October 13, 2026. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.